The FDA on 16 November 2011, approved Jakafi(ruxolitinib),from Incyte/Novartis, the first drug approved to specifically treat patients with the bone...
Incyte Corporation has announced the Phase III RESPONSE-2 study of Jakafi (ruxolitinib) met its primary endpoint in patients with polycythemia...
Incyte Corporation announced top-line results of the Phase II, randomized, double-blind, placebo-controlled RECAP trial of Jakavi/Jakafi (ruxolitinib), its oral JAK1...
Novartis has announced that five-year treatment with Jakafi (ruxolitinib) suggested an overall survival advantage for patients with myelofibrosis (MF), despite...
An agreement has been reached with the FDA and Incyte Corporation to conduct a Phase III registrational studies of Jakafi/Jakavi...
Incyte Corporation has announced that the FDA has approved Jakafi (ruxolitinib) for the treatment of steroid-refractory acute GVHD in adult...
Four-year data confirms efficacy and safety of Jakafi in polycythemia vera
Incyte announced that the Phase III REACH3 study evaluating Jakafi (ruxolitinib) in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD) met its primary endpoint of superior overall response rate (ORR) at Week 24 compared to best available therapy (BAT).
Incyte has announced that the FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi) for treatment of steroid-refractory chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.